Candel Therapeutics (CADL) Corporate presentation summary

Pipeline overview and clinical programs

• Aglatimagene besadenovec (CAN-2409) is an off-the-shelf pan-solid tumor therapy with positive phase 3 results in prostate cancer and phase 2a results in pancreatic and NSCLC cancers.

• Linoserpaturev (CAN-3110) is an oncolytic HSV-1 virus with proof of concept in recurrent high-grade glioma and published data in top journals.

• Both assets have received multiple FDA designations, including RMAT, Fast Track, and Orphan Drug status.

• The company is advancing a "pipeline in a product" strategy, targeting several large indications.

• Precommercialization activities and funding agreements are in place to support future launches.

Financial position and corporate highlights

• Cash and cash equivalents were $119.7 million as of December 31, 2025, with additional funds from a February 2026 equity offering.

• Entered a $130 million term loan facility and a $100 million royalty funding agreement, contingent on regulatory approval.

• Expected financial runway extends into Q1 2028.

• Strong executive team and research advisory board with leading oncology and immunology experts.

Aglatimagene in prostate cancer: clinical and commercial opportunity

• Phase 3 trial in intermediate- to high-risk localized prostate cancer (n=745) met its primary endpoint, showing a 30% risk reduction in disease recurrence (HR=0.70, p=0.0155).

• Significant improvements in prostate cancer-specific DFS (HR=0.62, p=0.0046), PSA nadir rates, and pathological complete response at 2 years (80.4% vs 63.6%).

• Safety profile was favorable, with lower rates of serious adverse events and discontinuations compared to placebo.

• U.S. addressable market for aglatimagene in prostate cancer estimated at $10–16 billion, with strong payor and physician support for reimbursement.

• Pre-launch commercial activities and payer engagement are underway, with BLA submission expected in Q4 2026.